Revance Therapeutics Inc
NASDAQ:RVNC

Watchlist Manager
Revance Therapeutics Inc Logo
Revance Therapeutics Inc
NASDAQ:RVNC
Watchlist
Price: 3.65 USD Market Closed
Market Cap: 381m USD

Revance Therapeutics Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Revance Therapeutics Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Revance Therapeutics Inc
NASDAQ:RVNC
EPS (Diluted)
-$1
CAGR 3-Years
26%
CAGR 5-Years
13%
CAGR 10-Years
2%
Johnson & Johnson
NYSE:JNJ
EPS (Diluted)
$10
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
EPS (Diluted)
$2
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
EPS (Diluted)
$1
CAGR 3-Years
-31%
CAGR 5-Years
4%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
EPS (Diluted)
$7
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
EPS (Diluted)
$20
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
25%
No Stocks Found

Revance Therapeutics Inc
Glance View

Market Cap
382.9m USD
Industry
Pharmaceuticals

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 495 full-time employees. The company went IPO on 2014-02-06. The firm is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The firm is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. The company offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.

RVNC Intrinsic Value
5.93 USD
Undervaluation 38%
Intrinsic Value
Price

See Also

What is Revance Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-1.8 USD

Based on the financial report for Sep 30, 2024, Revance Therapeutics Inc's EPS (Diluted) amounts to -1.8 USD.

What is Revance Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
2%

Over the last year, the EPS (Diluted) growth was 63%. The average annual EPS (Diluted) growth rates for Revance Therapeutics Inc have been 26% over the past three years , 13% over the past five years , and 2% over the past ten years .

Back to Top